Lead Product(s) : Quemliclustat
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Taiho Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Quemliclustat is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Pancreatic Ductal.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 23, 2024
Lead Product(s) : Quemliclustat
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Taiho Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Quemliclustat,Etrumadenant,Zimberelimab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Taiho Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Taiho Exercises License Option for Quemliclustat in Japan and Asia
Details : Under the license agreement, Taiho will further support the development & commercialization of AB680 (quemliclustat) & will operationalize the PRISM-1 study in Japan as part of its mission.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 08, 2024
Lead Product(s) : Quemliclustat,Etrumadenant,Zimberelimab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Taiho Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Quemliclustat,Paclitaxel,Zimberelimab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Gilead Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Quemliclustat-Based Regimens Show Promising Survival in Metastatic Pancreatic Cancer
Details : AB680 (quemliclustat) is an investigational small molecule CD73 inhibitor in phase 1 development, evaluated in combination with chemotherapy for treatment-naïve metastatic pancreatic cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 16, 2024
Lead Product(s) : Quemliclustat,Paclitaxel,Zimberelimab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Gilead Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Quemliclustat,Paclitaxel,Zimberelimab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Quemliclustat-Based Regimens Show Survival Promise in Metastatic Pancreatic Cancer
Details : AB680 (quemliclustat) is an investigational CD73 inhibitor undergoing phase 1 trials in combination with zimberelimab and chemotherapy for metastatic pancreatic cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 16, 2024
Lead Product(s) : Quemliclustat,Paclitaxel,Zimberelimab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Quemliclustat
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Arcus Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Quemliclustat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 23, 2023
Lead Product(s) : Quemliclustat
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Arcus Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Quemliclustat,Paclitaxel,Zimberelimab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Preliminary data from the first dose-escalation cohorts, reported in an abstract released today, demonstrate encouraging signs of clinical activity for AB680 in combination with zimberelimab (anti-PD-1 antibody) and chemotherapy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 11, 2021
Lead Product(s) : Quemliclustat,Paclitaxel,Zimberelimab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Quemliclustat
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers
Details : AB680 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 05, 2020
Lead Product(s) : Quemliclustat
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable